Erythropoietin

The assessment of effectiveness based on: epoetin alfa treatment schedule (dose and timing), hemoglobin effect, response to treatment (independent of blood transfusion), mean time to response, # of blood transfusions given, and iron supplementation

Perioperative allogeneic red blood cell transfusion volume

Compare Hb level after treatment with EPO associated with iron treatment by oral or intravenous route

endothelial function and atherosclerosis

Mean change in haemoglobin levels

Changes in serum protein isoforms measured by proteomics

Haemoglobin Concentration

Treatment failure (changes in hemoglobin levels)

Changes in CD71 expression

Cognitive function

Number of patients who receive an allogenic red blood cell transfusion during the study, during each chemotherapy cycle, and at 4 weeks after the last administration of chemotherapy

Mean time taken to achieve target hemoglobin (Hb) levels range (10-12 g/dL) During Efficacy Evaluation Period (EEP)

Hb level, decline in renal function, 24h proteinuria, creatinine clearance.

Decrease in Delayed Graft Function

Percentage of patients with undetectable RNA-HCV

Cost of Erythropoiesis Stimulating Agent

Dimensional changes

Change in Hb concentration between baseline and efficacy evaluation period (EEP).

Subject preference

change in hemoglobin

Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)

Overall Survival (OS)

TSAT (transferrin saturation), serum albumin, serum ferritin, serum transferrin, serum C reactive protein

Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.

Ratio of weekly dose at the evaluation period to the weekly dose at baseline

Anti-Erythropoietin (EPO) Antibodies

Proportion of patients in each treatment group, overall, and within each baseline hemoglobin group requiring blood transfusion following major orthopedic surgery

Change from baseline in the average hemoglobin (Hb)

Change in the patient-reported Pediatric Quality of Life Inventory (PedsQL Inventory) from baseline to the last assessment.

Change From Baseline to the Maximum Hemoglobin Level During Stage 2 (Week 9 Through Week 21).

Proportion of patients without transfusion after first month.

The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL during the evaluation phase

Left ventricular ejection fraction measured by magnetic resonance imaging

Mean Change From Baseline to the Highest Hemoglobin up to Day 71

Percentage of Patients Able to Maintain Hemoglobin (Hb) Within 10-12 g/dL

Global retinal nerve fibre layer thickness (RNFLT-G)

Change of hemoglobin levels at correction phase (baseline vs end of treatment)

- Hemoglobin concentration

The treatment response

Hemoglobin Level in blood

Percentage of Participants With Response to Treatment

Number of red blood cell transfusions

Percent of patients that achieved a hematopoietic response, defined as a Hb increase >= 2 g/dL and/or Hb = 12 g/dL during the study independent of transfusion within 28 days

Clinical Scoring

Improvement of ASIA Impairment Scale of at least 1 grade. Score on ASIA Scale and a ASIA Impairment Scale are an inclusion criteria, then at 3rd, 7th, 14th, 30th, 60th, 90th days

Number of Participants With Treatment-emergent Adverse Events

Death or moderate or severe disability at 18-22 months of age

Change from Baseline Visual Capacity

Left ventricular ejection fraction 6 weeks after primary PCI, measured with planar radionuclide ventriculography

Exercise tolerance

Proportion of subjects whose baseline score on the subjective FCST correctly estimates the baseline MHST score

Hemoglobin (Hb) Change From Baseline to Study Week 7

Change From Baseline in Hemoglobin (Hgb) at Week 4

Primary outcome measure (Mean (SD) of thalamic NAA level)

To evaluate the efficacy of association of Erythropoetin and ATRA in patients with low risk myelodysplastic syndromes

Erythroid response at 12 weeks according to IWG 2000 (major and minor hematologic improvement) and IWG 2006 criteria

Bleeding time

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) Events (NCI-CTCAE V5.0).

Modeled Hemoglobin (Hgb) Change From Baseline (Pre-dose on Day 1) at 4 Weeks of Treatment

Biological response rate for each group.

Percentage of Participants With Hematological Response of the Erythropoetic System (HI-E) - Core Phase

The Number of Patients Who Developed Peripheral Sensory Neuropathy (National Cancer Institute Common Toxicity Criteria (NCI CTC) Score >= 1) at Week 12.

To assess changes in fatigue in patients at least 18 years old with chronic rheumatoid arthritis (RA) and chronic anemia (Hb < 11.0 g/dL) due to ACD receiving weekly s.c. doses of PROCRIT versus placebo.

days of acute renal failure

The primary endpoint is the hemoglobin response rate, defined as the proportion of subjects who achieve at least a 1 gram per deciliter hemoglobin increase from baseline by Week 17.

To assess the change in physical function from baseline to end of study as measured by the Short Physical Performance Battery (SPPB) summary score.

Anemia correction

Functional status of the participants after 6 months of procedure assessed by modified Rankin Scale.

Assessment of visual acuity

Pharmacokinetic profiling of Aranesp® in HF pts

AUC0-t